Celldex Therapeutics (CLDX) Accumulated Expenses (2010 - 2026)

Celldex Therapeutics' Accumulated Expenses history runs 17 years deep, the most recent figure standing at $38.4 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 50.92% year-over-year to $38.4 million in Q1 2026; TTM through Mar 2026 was $38.4 million, a 50.92% increase from a year earlier, with the FY2025 full-year figure at $47.0 million, up 306.54% from the prior year.
• Accumulated Expenses slipped to $38.4 million in Q1 2026 per CLDX's latest filing, from $47.0 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $47.0 million in Q4 2025 and bottomed at $7.5 million in Q4 2022.
• The 5-year median for Accumulated Expenses is $17.5 million (2024), against an average of $20.2 million.
• Across the five-year window, Accumulated Expenses plunged 37.28% in 2022 and jumped 306.54% in 2025, its largest moves.
• Year by year, Accumulated Expenses stood at $7.5 million in 2022, then climbed by 24.21% to $9.3 million in 2023, then advanced by 23.75% to $11.6 million in 2024, then surged by 306.54% to $47.0 million in 2025, then retreated by 18.31% to $38.4 million in 2026.
• Per Business Quant, the three latest CLDX Accumulated Expenses figures stand at $38.4 million (Q1 2026), $47.0 million (Q4 2025), and $39.7 million (Q3 2025).